Payment overview · 2025
General Payments
$397.68
25 reported records · 12 companies
Healthcare provider profile · identity verified
Jessica Mccool, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COUNCIL BLUFFS, IA · NPI 1053600296
Verified facts
What the public records show
CMS Open Payments records show Jessica Mccool, M.D. received $397.68 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.89 | 34.2% | 11 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $47.44 | 11.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.07 | 10.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $31.00 | 7.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.23 | 7.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.27 | 5.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.25 | 4.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.00 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.19 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.91 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.78 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.65 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $397.68 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $114.72 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.91 | 7 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $47.44 | 1 | 2025 |
Source payment records
|
|||||
| FIXOS Normalized: fixos |
Device | Stryker Corporation | $47.44 | 1 | 2025 |
Source payment records
|
|||||
| VARIAX Normalized: variax |
Device | Stryker Corporation | $47.44 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $35.23 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 346 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
346 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
346 | 45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 944 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 527 | 106 |
| Gabapentin | Gabapentin | 500 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 489 | 105 |
| Furosemide | Furosemide | 440 | 65 |
| Losartan Potassium | Losartan Potassium | 404 | 93 |
| Lisinopril | Lisinopril | 361 | 84 |
| Sertraline Hcl | Sertraline Hcl | 360 | 72 |
| Omeprazole | Omeprazole | 347 | 87 |
| Eliquis | Apixaban | 346 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 66 |
| Potassium Chloride | Potassium Chloride | 321 | 63 |
| Metformin Hcl | Metformin Hcl | 271 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 48 |
| Trazodone Hcl | Trazodone Hcl | 204 | 45 |
| Glipizide Er | Glipizide | 193 | 42 |
| Meloxicam | Meloxicam | 178 | 37 |
| Simvastatin | Simvastatin | 171 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 50 |
| Donepezil Hcl | Donepezil Hcl | 163 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 23 |
| Myrbetriq | Mirabegron | 154 | 15 |
| Celecoxib | Celecoxib | 151 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 151 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 32 |
| Alendronate Sodium | Alendronate Sodium | 144 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 138 | 19 |
| Xarelto | Rivaroxaban | 137 | 15 |
| Allopurinol | Allopurinol | 134 | 22 |
| Alprazolam | Alprazolam | 131 | 32 |
| Bupropion Xl | Bupropion Hcl | 131 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 24 |
| Tramadol Hcl | Tramadol Hcl | 119 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 15 |
| Lorazepam | Lorazepam | 110 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 28 |
| Montelukast Sodium | Montelukast Sodium | 103 | 24 |
| Ozempic | Semaglutide | 100 | 16 |
| Carvedilol | Carvedilol | 96 | 25 |
| Spironolactone | Spironolactone | 94 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 13 |
| Metformin Hcl Er | Metformin Hcl | 91 | 25 |
| Mounjaro | Tirzepatide | 90 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | 23 |
| Buspirone Hcl | Buspirone Hcl | 86 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 29 |
| Torsemide | Torsemide | 80 | 14 |
| Jardiance | Empagliflozin | 79 | 16 |
| Ezetimibe | Ezetimibe | 78 | 15 |
| Pregabalin | Pregabalin | 77 | 18 |
| Famotidine | Famotidine | 70 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 66 | 14 |
| Fenofibrate | Fenofibrate | 63 | 16 |
| Mirtazapine | Mirtazapine | 62 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 14 |
| Memantine Hcl | Memantine Hcl | 59 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | 12 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Baclofen | Baclofen | 57 | 11 |
| Gemtesa | Vibegron | 57 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 57 | suppressed |
| Prednisone | Prednisone | 55 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 51 | 12 |
| Finasteride | Finasteride | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 11 |
| Synthroid | Levothyroxine Sodium | 46 | 12 |
| Benazepril Hcl | Benazepril Hcl | 45 | 11 |
| Doxepin Hcl | Doxepin Hcl | 45 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Cephalexin | Cephalexin | 39 | 23 |
| Ketoconazole | Ketoconazole | 39 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 20 |
| Risperidone | Risperidone | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Nystatin | Nystatin | 31 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | 11 |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Colchicine | Colchicine | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Glipizide | Glipizide | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 18 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 17 |
| Diazepam | Diazepam | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $397.68 · 25 records | ABBVIE INC. | AUGMENT INJECTABLE, Cologuard Collection Kit, ELIQUIS, EVENITY, FIXOS, JOURNAVX, NURTEC ODT, Ohtuvayre, PROLIA, QULIPTA, REXULTI, UBRELVY, VARIAX, VRAYLAR, VYNDAQEL, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error